Appointment

From: Carolyn Balkenhol [/O=THERANOS ORGANIZATION/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=CBALKENHOL]
Sent: 3/30/2009 7:27:04 PM
To: Elizabeth Holmes [eholmes@theranos.com]; Marc Thibonnier [mthibonnier@theranos.com]; Seth Michelson [smichelson@theranos.com]; Tim Kemp [kemptm@theranos.com]; Stefan Hristu [shristu@theranos.com]; Gary Frenzel [gfrenzel@theranos.com]; Ian Gibbons [igibbons@theranos.com]; Daniel Young [dyoung@theranos.com]; Kelley Harrison [kharrison@theranos.com]

Subject: Copy: Schering-Plough folks here - Draft agenda attached

Start: 5/5/2009 3:00:00 PM
End: 5/6/2009
Show Time As: Busy

Required Attendees: Elizabeth Holmes; Marc Thibonnier; Seth Michelson; Tim Kemp; Stefan Hristu; Gary Frenzel; Ian Gibbons; Daniel Young; Kelley Harrison

I'm sure you'll only be required during a portion of this meeting, but I wanted to let you know about it, at any rate; also, I assume they'll want a tour of the facility.
Thanks,
Carolyn

Participants from Schering-Plough:

Bart van Hoogstraten, M.D., Ph.D. - Director, Clinical; Egbert Biesheuvel; Jean-Louis Saillot; Constance Cullen - Director, Preclinical & Clinical bioanalytics; Malaz Abutarif, Ph.D., G.C.P.M, M.B.A. - Principal Scientist - PK PD and PM group; Robert Fick, M.D. - Senior Group Director - Experimental Pathology & Pharmacology; Mark Watson, M.D., Ph.D. - Director for ECREM; Ferdous Gheyas, Ph.D. - Associate Director, Statistics

Schering-Plough requested agenda items:
1. Assay validation process
2. Quality oversight in place
3. Timing for validations
4. Process for development of proprietary assays such as those for drug levels or anti-drug antibodies
5. Multiplexing process - how are multiplexed assays validated?
6. Computer system validation - how is result integrity ensured?
7. Protection of patient confidentiality - how do we ensure that HIPA requirements will be met?
8. Incurred sample reanalysis

Meeting at Theranos Headquarters
3200 Hillview Avenue, Palo Alto, California
5 May 2009
8:00 a.m. – 5:00 p.m.

8:00 a.m. Light breakfast and introductions

8:30 a.m. Background on Theranos, Inc.

8:45 a.m. Theranos Point-of-Care Systems – questions from Schering-Plough

1. Assay development and validation
   - Development process (including proprietary drug level and antibodies assays)
   - Multiplexing process
   - Validation process
   - Validation program timing
   - Incurred sample reanalysis
2. Quality
   - Confidentiality & HIPAA compliance
3. Software validation – ensuring result integrity

10:45a Break

11:00 a.m. Theranos Operating System

1. Data Integration
2. Modeling and Simulation

12:15 p.m. Lunch

1:00 p.m. Theranos Case Studies

1. Accelerating study timelines
2. Rapid label optimization and expansion pre-approval and in post-marketing studies

2:30 p.m. Customized analytical system for Schering-Plough

1. Inflammation and Rheumatoid Arthritis System
2. TRA System

3:45 p.m. Break

4:00 p.m. Tour

4:30 p.m. Discussion and action items

Schering-Plough Participants
Malaz Abutarif, Ph.D., G.C.P.M, M.B.A. – Principal Scientist - PK PD and PM group
Egbert Biesheuvel
Constance Cullen – Director, Preclinical & Clinical bioanalytics
Robert Fick, M.D. – Senior Group Director - Experimental Pathology & Pharmacology
Ferdous Gheyas, Ph.D. – Associate Director, Statistics
Jim McLeod – by phone?
Jean-Louis Saillot
Mark Watson, M.D., Ph.D. – Director for ECREM
Bart van Hoogstraten, M.D., Ph.D. – Director, Clinical

Theranos Participants
Gary Frenzel – Vice President, Assay Development
Ian Gibbons, PhD – Senior Director, Assay Development
Elizabeth Holmes – President & CEO
Tim Kemp – Theranos Fellow
Seth Michelson, MA, MS, PhD – Principal Scientist, Biomathematician
Marc Thibonnier, MD, MSc, FAHA – Chief Medical Officer
Daniel Young, PhD – Senior Modeler